Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Surg Res ; 151(1): 74-9, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18468627

RESUMO

BACKGROUND: During some surgical interventions, temporary occlusion of the hepatic blood supply may cause ischemia-reperfusion (IR) injury. Recent studies suggest that type 3 phosphodiesterase inhibitors may have a beneficial effect on liver IR injury. The aim of this study was to investigate whether amrinone, a type 3 phosphodiesterase inhibitor, could have a protective effect on liver having experimental liver IR injury. MATERIALS AND METHODS: Sixty Wistar albino rats were randomly divided into three groups. The IR and amrinone groups were subjected to 1 h total hepatic ischemia, followed by 2 h of reperfusion. The sham group underwent midline laparotomy only. Amrinone 10 microg/kg/min was infused to the amrinone group during the 3 h of the IR period. Histopathological examination, biochemical liver function, and liver adenosine triphosphate concentration after reperfusion and survival rate on the seventh day after the IR insult were recorded. RESULTS: Serum aspartate aminotransferase, alanine aminotransferase, lactic dehydrogenase levels, and histological damage scores in the amrinone and IR groups were significantly higher compared with the sham group (P < 0.01). However, all of these values were significantly lower in the amrinone group than in the IR group (P < 0.05). Liver adenosine triphosphate levels and the rat survival rate in the amrinone and IR groups were significantly lower than those in the sham group (P < 0.01). However, these values were significantly higher in the amrinone group compared to those in the IR group (P < 0.01). CONCLUSIONS: These results suggest that amrinone plays a significant role in the protection of liver against IR injury and that this treatment may be a novel pharmacological agent for safe and efficient liver surgery.


Assuntos
Amrinona/farmacologia , Hepatopatias/prevenção & controle , Inibidores de Fosfodiesterase/farmacologia , Traumatismo por Reperfusão/prevenção & controle , Vasodilatadores/farmacologia , Trifosfato de Adenosina/metabolismo , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Biópsia , Cálcio/metabolismo , AMP Cíclico/metabolismo , Modelos Animais de Doenças , L-Lactato Desidrogenase/sangue , Fígado/irrigação sanguínea , Fígado/metabolismo , Fígado/patologia , Hepatopatias/metabolismo , Masculino , Agregação Plaquetária/efeitos dos fármacos , Ratos , Ratos Wistar , Traumatismo por Reperfusão/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...